Veracyte Inc. (VCYT) Insider Trading

Last 12 months

Insiders sold $21.1M and bought nothing on the open market.

93% of the selling was scheduled in advance under 10b5-1 plans. VP, Chief Accounting Officer Jonathan Wygant sold $1.09M on May 22, 35% of their stake, outside a plan. The last open-market buy by an executive or director was in Jun 2022.

Net open-market

−$21.1M

0 buys · 34 sales

Under a 10b5-1 plan

93%

of the value sold

Insiders who bought / sold

0 / 11

executives and directors

Last open-market buy

Jun 2022

Jun 10, 2022

Get an email when VCYT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 19	Muna Bhanji Director	Sold10b5-1 plan	1,864	$43.70	$81k	4.4%	Form 4
Sep 21	John Leite Global Chief Commercial Off	Sold10b5-1 plan	4,015	$40.00	$161k	3.1%	Form 4
Sep 14	Jens Holstein Director	Sold10b5-1 plan	5,000	$40.95	$205k	15%	Form 4
Sep 4	Annie McGuire EVP, General Counsel	Sold10b5-1 plan 2 parts	3,254	$43.09 average	$140k	2.4%	Form 4
Sep 4	Rebecca Chambers Chief Financial Officer	Sold10b5-1 plan 2 parts	3,652	$43.10 average	$157k	2.2%	Form 4
Sep 4	Phillip G. Febbo Chief Scientific & Med Officer	Sold10b5-1 plan 2 parts	13,110	$43.05 average	$564k	9.0%	Form 4
Sep 1	Muna Bhanji Director	Sold10b5-1 plan	1,864	$42.97	$80k	4.2%	Form 4
Jun 18	Karin Eastham Director	Sold10b5-1 plan 2 parts	3,729	$52.89 average	$197k	20%	Form 4
Jun 4	John Leite Global Chief Commercial Off	Sold10b5-1 plan	13,975	$50.07	$700k	9.6%	Form 4
Jun 4	Annie McGuire EVP, General Counsel	Sold10b5-1 plan 2 parts	3,176	$49.76 average	$158k	2.3%	Form 4
Jun 4	Rebecca Chambers Chief Financial Officer	Sold10b5-1 plan 2 parts	3,561	$49.73 average	$177k	2.0%	Form 4
Jun 4	Marc Stapley Chief Executive Officer	Sold10b5-1 plan	138,051	$50.12	$6.92M	24%	Form 4
May 22	Jonathan Wygant VP, Chief Accounting Officer	SoldNo plan	24,000	$45.40	$1.09M	35%	Form 4
May 20	Robert S Epstein Director	Sold10b5-1 plan	10,000	$44.01	$440k	16%	Form 4
May 6	Annie McGuire SVP, General Counsel	Sold10b5-1 plan 2 parts	10,204	$39.03 average	$398k	6.6%	Form 4
Mar 4	John Leite Chief Commercial Officer-CLIA	Sold10b5-1 plan	5,260	$35.19	$185k	4.7%	Form 4
Mar 4	Annie McGuire SVP, General Counsel	Sold10b5-1 plan 2 parts	6,658	$35.55 average	$237k	6.6%	Form 4
Mar 4	Rebecca Chambers Chief Financial Officer	Sold10b5-1 plan 2 parts	18,341	$36.14 average	$663k	12%	Form 4
Mar 4	Marc Stapley Chief Executive Officer	Sold10b5-1 plan 2 parts	45,523	$35.98 average	$1.64M	11%	Form 4
Mar 2	Phillip G. Febbo Chief Scientific & Med Officer	Sold10b5-1 plan	13,425	$36.16	$485k	10%	Form 4
Dec 16, 2025	Annie McGuire SVP, General Counsel	Sold10b5-1 plan 2 parts	10,739	$43.14 average	$463k	14%	Form 4
Dec 5, 2025	Karin Eastham Director	Sold10b5-1 plan 3 parts	20,000	$45.45 average	$909k	60%	Form 4
Dec 4, 2025	John Leite Chief Commercial Officer-CLIA	Sold10b5-1 plan	1,278	$47.51	$61k	1.5%	Form 4
Dec 4, 2025	Annie McGuire SVP, General Counsel	Sold10b5-1 plan 2 parts	1,422	$47.30 average	$67k	1.8%	Form 4
Dec 4, 2025	Rebecca Chambers Chief Financial Officer	Sold10b5-1 plan 2 parts	13,278	$46.84 average	$622k	11%	Form 4
Dec 4, 2025	Marc Stapley Chief Executive Officer	Sold10b5-1 plan 2 parts	7,668	$47.09 average	$361k	2.4%	Form 4
Nov 25, 2025	John Leite Chief Commercial Officer-CLIA	Sold10b5-1 plan	2,808	$50.00	$140k	3.2%	Form 4
Nov 25, 2025	Evan/ Fa Jones Director	Sold10b5-1 plan	1,106	$50.25	$56k	3.6%	Form 4
Nov 20, 2025	Jens Holstein Director	Sold10b5-1 plan 3 parts	10,000	$42.36 average	$424k	27%	Form 4
Nov 7, 2025 – Nov 10, 2025	Jonathan Wygant VP, Chief Accounting Officer	SoldNo plan 2 parts	10,920	$41.20 average	$450k	22%	Form 4
Nov 5, 2025	Annie McGuire SVP, General Counsel	Sold10b5-1 plan	6,466	$40.00	$259k	7.2%	Form 4
Nov 5, 2025	Rebecca Chambers Chief Financial Officer	Sold10b5-1 plan	7,000	$41.00	$287k	5.3%	Form 4
Nov 5, 2025	Karin Eastham Director	Sold10b5-1 plan	9,674	$40.02	$387k	42%	Form 4
Nov 5, 2025	Evan/ Fa Jones Director	Sold10b5-1 plan 6 parts	43,196	$45.06 average	$1.95M	59%	Form 4
Oct 6, 2025	Phillip G. Febbo Chief Scientific & Med Officer	Sold10b5-1 plan	8,349	$36.02	$301k	8.3%	Form 4
Oct 1, 2025	John Leite Chief Commercial Officer-CLIA	Sold10b5-1 plan	2,539	$35.00	$89k	2.8%	Form 4
Oct 1, 2025	Annie McGuire SVP, General Counsel	Sold10b5-1 plan	2,160	$35.00	$76k	2.4%	Form 4
Oct 1, 2025	Robert S Epstein Director	Sold10b5-1 plan	21,473	$35.08	$753k	26%	Form 4
Sep 19, 2025	Annie McGuire SVP, General Counsel	Sold10b5-1 plan	2,283	$33.69	$77k	2.4%	Form 4
Sep 4, 2025	Marc Stapley Chief Executive Officer	Sold10b5-1 plan	7,667	$30.41	$233k	2.2%	Form 4

Oct 1910b5-1 plan
Muna Bhanji
Director · sold 1,864 at $43.70
$81k
4.4% of stake
Sep 2110b5-1 plan
John Leite
Global Chief Commercial Off · sold 4,015 at $40.00
$161k
3.1% of stake
Sep 1410b5-1 plan
Jens Holstein
Director · sold 5,000 at $40.95
$205k
15% of stake
Sep 410b5-1 plan
Annie McGuire
EVP, General Counsel · sold 3,254 at avg $43.09
$140k
2.4% of stake
Sep 410b5-1 plan
Rebecca Chambers
Chief Financial Officer · sold 3,652 at avg $43.10
$157k
2.2% of stake
Sep 410b5-1 plan
Phillip G. Febbo
Chief Scientific & Med Officer · sold 13,110 at avg $43.05
$564k
9.0% of stake
Sep 110b5-1 plan
Muna Bhanji
Director · sold 1,864 at $42.97
$80k
4.2% of stake
Jun 1810b5-1 plan
Karin Eastham
Director · sold 3,729 at avg $52.89
$197k
20% of stake
Jun 410b5-1 plan
John Leite
Global Chief Commercial Off · sold 13,975 at $50.07
$700k
9.6% of stake
Jun 410b5-1 plan
Annie McGuire
EVP, General Counsel · sold 3,176 at avg $49.76
$158k
2.3% of stake
Jun 410b5-1 plan
Rebecca Chambers
Chief Financial Officer · sold 3,561 at avg $49.73
$177k
2.0% of stake
Jun 410b5-1 plan
Marc Stapley
Chief Executive Officer · sold 138,051 at $50.12
$6.92M
24% of stake
May 22No plan
Jonathan Wygant
VP, Chief Accounting Officer · sold 24,000 at $45.40
$1.09M
35% of stake
May 2010b5-1 plan
Robert S Epstein
Director · sold 10,000 at $44.01
$440k
16% of stake
May 610b5-1 plan
Annie McGuire
SVP, General Counsel · sold 10,204 at avg $39.03
$398k
6.6% of stake
Mar 410b5-1 plan
John Leite
Chief Commercial Officer-CLIA · sold 5,260 at $35.19
$185k
4.7% of stake
Mar 410b5-1 plan
Annie McGuire
SVP, General Counsel · sold 6,658 at avg $35.55
$237k
6.6% of stake
Mar 410b5-1 plan
Rebecca Chambers
Chief Financial Officer · sold 18,341 at avg $36.14
$663k
12% of stake
Mar 410b5-1 plan
Marc Stapley
Chief Executive Officer · sold 45,523 at avg $35.98
$1.64M
11% of stake
Mar 210b5-1 plan
Phillip G. Febbo
Chief Scientific & Med Officer · sold 13,425 at $36.16
$485k
10% of stake
Dec 16, 202510b5-1 plan
Annie McGuire
SVP, General Counsel · sold 10,739 at avg $43.14
$463k
14% of stake
Dec 5, 202510b5-1 plan
Karin Eastham
Director · sold 20,000 at avg $45.45
$909k
60% of stake
Dec 4, 202510b5-1 plan
John Leite
Chief Commercial Officer-CLIA · sold 1,278 at $47.51
$61k
1.5% of stake
Dec 4, 202510b5-1 plan
Annie McGuire
SVP, General Counsel · sold 1,422 at avg $47.30
$67k
1.8% of stake
Dec 4, 202510b5-1 plan
Rebecca Chambers
Chief Financial Officer · sold 13,278 at avg $46.84
$622k
11% of stake
Dec 4, 202510b5-1 plan
Marc Stapley
Chief Executive Officer · sold 7,668 at avg $47.09
$361k
2.4% of stake
Nov 25, 202510b5-1 plan
John Leite
Chief Commercial Officer-CLIA · sold 2,808 at $50.00
$140k
3.2% of stake
Nov 25, 202510b5-1 plan
Evan/ Fa Jones
Director · sold 1,106 at $50.25
$56k
3.6% of stake
Nov 20, 202510b5-1 plan
Jens Holstein
Director · sold 10,000 at avg $42.36
$424k
27% of stake
Nov 7, 2025 – Nov 10, 2025No plan
Jonathan Wygant
VP, Chief Accounting Officer · sold 10,920 at avg $41.20
$450k
22% of stake
Nov 5, 202510b5-1 plan
Annie McGuire
SVP, General Counsel · sold 6,466 at $40.00
$259k
7.2% of stake
Nov 5, 202510b5-1 plan
Rebecca Chambers
Chief Financial Officer · sold 7,000 at $41.00
$287k
5.3% of stake
Nov 5, 202510b5-1 plan
Karin Eastham
Director · sold 9,674 at $40.02
$387k
42% of stake
Nov 5, 202510b5-1 plan
Evan/ Fa Jones
Director · sold 43,196 at avg $45.06
$1.95M
59% of stake
Oct 6, 202510b5-1 plan
Phillip G. Febbo
Chief Scientific & Med Officer · sold 8,349 at $36.02
$301k
8.3% of stake
Oct 1, 202510b5-1 plan
John Leite
Chief Commercial Officer-CLIA · sold 2,539 at $35.00
$89k
2.8% of stake
Oct 1, 202510b5-1 plan
Annie McGuire
SVP, General Counsel · sold 2,160 at $35.00
$76k
2.4% of stake
Oct 1, 202510b5-1 plan
Robert S Epstein
Director · sold 21,473 at $35.08
$753k
26% of stake
Sep 19, 202510b5-1 plan
Annie McGuire
SVP, General Counsel · sold 2,283 at $33.69
$77k
2.4% of stake
Sep 4, 202510b5-1 plan
Marc Stapley
Chief Executive Officer · sold 7,667 at $30.41
$233k
2.2% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch VCYT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Services-Medical Laboratories

CDNACareDx Inc.

BLLNBillionToOne, Inc.

CSTLCastle Biosciences, Inc.

FLGTFulgent Genetics Inc.

CAICaris Life Sciences, Inc.

GRALGrail, Inc.

BDSXBiodesix Inc.

BNRBurning Rock Biotech Ltd

Spot a number that looks wrong? Check it in VCYT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing VCYT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.